Corrigendum to “Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo” (Molecular Therapy (2016) 24(6) (1106–1116) (S1525001616303781) (10.1038/mt.2016.60));Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth in Vivo

Molecular Therapy

Volumn 24, Issue 6, 2016, Pages 1106-1116

  Yoon, Sorah ^a   Huang, Kai Wen ^b,c   Reebye, Vikash ^d   Mintz, Paul ^d   Tien, Yu Wen ^b   Lai, Hong Shiee ^b   Sætrom, Pål ^e   Reccia, Isabella ^d   Swiderski, Piotr ^a   Armstrong, Brian ^a   Jozwiak, Agnieszka ^a   Spalding, Duncan ^d   Jiao, Long ^d   Habib, Nagy ^d   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

2' FLUOROPYRIMIDINE RNA APTAMER; APTAMER; CCAAT ENHANCER BINDING PROTEIN ALPHA; MOLECULAR THERAPY AGENT; PROTEIN P21; SMALL ACTIVATING RNA; UNCLASSIFIED DRUG; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MAJOR CLINICAL STUDY; MITOSIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; CARCINOMA, PANCREATIC DUCTAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR CELL LINE; UPREGULATION;

ANIMALS; APTAMERS, NUCLEOTIDE; CARCINOMA, PANCREATIC DUCTAL; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; RNA; TREATMENT OUTCOME; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84973149548     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.197     Document Type: Erratum

References (34)

1. Jemal, A, Siegel, R, Ward, E, Hao, Y, Xu, J and Thun, MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Stathis, A and Moore, MJ (2010). Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7: 163-172.
3. (2011). Pancreatic cancer in the UK. Lancet 378: 1050.
4. Vincent, A, Herman, J, Schulick, R, Hruban, RH and Goggins, M (2011). Pancreatic cancer. Lancet 378: 607-620.
5. Alexakis, N, Halloran, C, Raraty, M, Ghaneh, P, Sutton, R and Neoptolemos, JP (2004). Current standards of surgery for pancreatic cancer. Br J Surg 91: 1410-1427.
6. Ghaneh, P, Costello, E and Neoptolemos, JP (2007). Biology and management of pancreatic cancer. Gut 56: 1134-1152.
7. Klinkenbijl, JH, Jeekel, J, Sahmoud, T, van Pel, R, Couvreur, ML, Veenhof, CH et al. (1999). Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230: 776-82; discussion 782.
8. Neoptolemos, JP, Stocken, DD, Friess, H, Bassi, C, Dunn, JA, Hickey, H et al.; European Study Group for Pancreatic Cancer. (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210.
9. Oettle, H, Post, S, Neuhaus, P, Gellert, K, Langrehr, J, Ridwelski, K et al. (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297: 267-277.
10. (2005). Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 54 (suppl. 5): v1-16.
11. Wong, HH and Lemoine, NR (2009). Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6: 412-422.
12. Fulda, S (2009). Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med 13: 1221-1227.
13. Eser, S, Schnieke, A, Schneider, G and Saur, D (2014). Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 111: 817-822.
14. Yamamoto, K, Tateishi, K, Kudo, Y, Sato, T, Yamamoto, S, Miyabayashi, K, et al. (2014). Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPalpha. Carcinogenesis 35: 2404-2414.
15. Li, LC, Okino, ST, Zhao, H, Pookot, D, Place, RF, Urakami, S et al. (2006). Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 103: 17337-17342.
16. Janowski, BA, Younger, ST, Hardy, DB, Ram, R, Huffman, KE and Corey, DR (2007). Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 3: 166-173.
17. Reebye, V, Sætrom, P, Mintz, PJ, Huang, KW, Swiderski, P, Peng, L et al. (2014). Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology 59: 216-227.
18. Junxia, W, Ping, G, Yuan, H, Lijun, Z, Jihong, R, Fang, L et al. (2010). Double strand RNA-guided endogeneous E-cadherin up-regulation induces the apoptosis and inhibits proliferation of breast carcinoma cells in vitro and in vivo. Cancer Sci 101: 1790-1796.
19. Ellington, AD and Szostak, JW (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
20. Tuerk, C (1997). Using the SELEX combinatorial chemistry process to find high affinity nucleic acid ligands to target molecules. Methods Mol Biol 67: 219-230.
21. Ulrich, H, Magdesian, MH, Alves, MJ and Colli, W (2002). In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J Biol Chem 277: 20756-20762.
22. Wang, J, Jiang, H and Liu, F (2000). In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection. RNA 6: 571-583.
23. Blank, M, Weinschenk, T, Priemer, M and Schluesener, H (2001). Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen. J Biol Chem 276: 16464-16468.
24. Daniels, DA, Chen, H, Hicke, BJ, Swiderek, KM and Gold, L (2003). A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 100: 15416-15421.
25. Hicke, BJ, Marion, C, Chang, YF, Gould, T, Lynott, CK, Parma, D et al. (2001). Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 276: 48644-48654.
26. Wilson, DS and Szostak, JW (1999). In vitro selection of functional nucleic acids. Annu Rev Biochem 68: 611-647.
27. Que-Gewirth, NS and Sullenger, BA (2007). Gene therapy progress and prospects: RNA aptamers. Gene Ther 14: 283-291.
28. Timchenko, NA, Wilde, M, Nakanishi, M, Smith, JR and Darlington, GJ (1996). CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev 10: 804-815.
29. Ciribilli, Y, Singh, P, Spanel, R, Inga, A and Borlak, J (2015). Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas. Oncotarget 6: 31569-31592.
30. Gragoudas, ES, Adamis, AP, Cunningham, ET Jr, Feinsod, M and Guyer, DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
31. Kim, YH, Sung, HJ, Kim, S, Kim, EO, Lee, JW, Moon, JY et al. (2011). An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Lett 313: 76-83.
32. Kumagai, T, Akagi, T, Desmond, JC, Kawamata, N, Gery, S, Imai, Y et al. (2009). Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 124: 827-833.
33. Yoon, S, Lee, G, Han, D, Song, JY, Kang, KS and Lee, YS (2010). Neutralization of infectivity of porcine circovirus type 2 (PCV2) by capsid-binding 2'F-RNA aptamers. Antiviral Res 88: 19-24.
34. Sefah, K, Shangguan, D, Xiong, X, O'Donoghue, MB and Tan, W (2010). Development of DNA aptamers using Cell-SELEX. Nat Protoc 5: 1169-1185.